Note: Descriptions are shown in the official language in which they were submitted.
81782937
RADIOPHARMACEUTICAL SYNTHESIS METHODS
RELATED APPLICATIONS
SUMMARY OF INVENTION
The invention is based on the unexpected finding that increased yields of
certain
radiopharmaccuticals can be achieved when particular filters are used to
sterilize solutions
comprising the radiopharmaceuticals. The filters are typically used in a final
sterilization step
following synthesis however it is to be understood that the invention is not
so limited and the
filters may be used in any step during or post-synthesis. The increased yield
achieved with
particular filters, in accordance with the invention, relates to the
differential retention properties
of the various filters analyzed. It was not recognized nor was it expected
prior to the invention
that particular filters would demonstrate the varied retention profiles
observed and documented
herein. Moreover, it could not have been predicted which of the tested filters
would be the best
performing based on the various known properties of the various filters (e.g.,
hydrophobicity,
etc.).
It was found in accordance with the invention that a filter comprised of
regenerated
cellulose (such as the Sartorius RC filter) and a filter comprised of
polytetrafluoroethylene (such
as the Millipore PTFE filter) were the best performing filters in terms of
lowest retention of the
filtered radiopharmaceutical. It is surprising that two such disparate filter
types would
nevertheless perform relatively equivalently and better than other filters
that are more similar to
one or the other of the RC or PTFE filters. As an example, a
polyvinylidenedifluoride (PVDF)
filter which is structurally more similar to PTFE than is RC nevertheless
performed less well
than did the RC filter in terms of reduced retention of the
radiopharmaceutical. Also
CA 2869398 2019-02-13
81782937
2
surprisingly, the matrix within which the radiopharmaceutical was provided was
not
changed, and it was able to tolerate different filters without compromise of
radiopharmaceutical yield.
In one aspect, the invention provides a method comprising passing a
composition
comprising an 18F-bearing radiopharmaceutical through a regenerated cellulose
filter or a
polytetrafluoroethylene filter, thereby achieving a filtered
radiopharmaceutical composition,
wherein the 18F-bearing radiopharmaceutical is:
0
)4N :C1
I I
0 0111
8F
flurpiridaz F 18
In another aspect, the invention provides a method as described herein,
wherein the
composition has a pH of about 5.8.
BRIEF DESCRIPTION OF FIGURES
FIG. 1 is a graph showing liquid transfer efficiency through selected filters.
FIG. 2 is a bar graph showing dependence of individual analyte retention on
overall
filtration rate.
FIG. 3 is a bar graph showing dependence of individual analyte retention on
overall
solution concentration.
FIG. 4 is a bar graph showing dependence of individual analyte retention on
filter
membrane composition.
FIG. 5 is a bar graph showing dependence of individual analyte retention on
filter
membrane and housing composition.
FIG. 6 is a graph showing the results of a flushing study.
CA 2869398 2019-02-13
81782937
2a
FIG. 7 is a bar graph showing dependence of individual analyte retention on
filter
size and membrane composition.
FIG. 8 is a bar graph showing a comparison of select filters.
FIG. 9 is a bar graph showing dependence of flurpiridaz F 18 retention on
selected
filters and synthesis modules.
DETAILED DESCRIPTION OF INVENTION
The method of the invention may be used to sterilize a radiopharmaceutical,
such
as an 18F-bearing radiopharmaceutical (i.e., a composition intended for in
vivo use,
typically as an imaging agent, that comprises 18F). It is to be understood
that the method
may also be used to sterilize other radiopharmaceuticals. The method of the
invention
may also be used to simply physically separate a radiopharmaceutical from
other agents
including degradation products, contaminants, and the like, regardless of
whether the
ultimate filtered solution is considered sterile.
Examples of 18F-bearing radiopharmaceuticals include but are not limited to
CA 2869398 2019-02-13
CA 02869398 2014-10-01
WO 2013/173004
PCT/US2013/036027
3
NC CN
I
OH 02N
_., 18F0 Me
18F N,' i iµii8F
HQ
11-00H N
Me \.------- OH
[189FDG (clogP = -2.01), [189FDDNP (clogP = 3.42) ,[189FMISO (clogP = -
0.54),
0
OH
18F Me
18R.........0 0 NH2
HO2C CO2H
[18F]FET (clogP = -1.39) [18F]ML-10 (clogP = 1.29)
,
0
MeI NANH
18F...õ......................õ0
I
N 0
Me0 = Me H
H O....3
Me
- Ft
Ho 18F
[18F]AV-133 (clogP = 2.39) [18FIFLT (clogP = -0.41)
, ,
\11,0
.--Y CI
CO2Me
0 4111) I
0===,...18F
flurpiridaz F 18 (clogP = 3.04) , and [18F]3-CIT (clogP = 4.42)
Other examples include florbetapir, and florbetaben (disclosed in US 7687052
and
7807135, respectively and shown below)
0 NHMe NHMe
1 \
18r ,
18FO 31 i 0
3
[leF]florbetapir (clogP = 3.52) [18F]florbetaben (clogP = 4.12)
CA 02869398 2014-10-01
WO 2013/173004 PCT/US2013/036027
4
In some aspects of the invention, the radiopharmaceutical has a structure as
in formula
(1),
0
R8
R R- R3
N R4
R7
R6
R5
(I),
wherein:
J is selected from N(R9), S, 0, C(=0), C(=0)0, NEICH2CH20, a bond, or
when present, K is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, C1-C6
alkyl,
heteroaryl, and an imaging moiety;
when present, L is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, C1-C6
alkyl,
heteroaryl, and an imaging moiety;
M is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, C1-C6 alkyl,
heteroaryl, and an
imaging moiety; or
L and M, together with the atom to which they are attached, form a three-,
four-, five-, or
six-membered carbocyclic ring;
Q is halo or haloalkyl;
n is 0, 1,2, or 3;
RI, R2, R7, and R9 are independently selected from hydrogen, C1-C6 alkyl, and
an
imaging moiety;
R3, R4, R5, and R6 are independently selected from hydrogen, halogen,
hydroxyl,
alkoxyalkyl, alkyloxy, C1-C6 alkyl, and an imaging moiety;
R8 is C1-C6 alkyl; and
Y is selected from a bond, carbon, and oxygen; provided that when Y is a bond,
K and L
are absent and M is selected from aryl and heteroaryl; and provided that when
Y is oxygen, K
and L are absent and M is selected from hydrogen, alkoxyalkyl, aryl, C1-C6
alkyl, and heteroaryl;
wherein each occurrence of alkoxyalkyl, alkyloxy, aryl, C1-C6 alkyl, and
heteroaryl is
optionally substituted with an imaging moiety,
CA 02869398 2014-10-01
WO 2013/173004
PCT/US2013/036027
provided that at least one imaging moiety is present in formula (I).
In some embodiments, J is 0; M is selected from alkoxyalkyl, alkyloxy, aryl,
Ci-C6 alkyl,
and heteroaryl, each optionally substituted with an imaging moiety; Q is halo
or haloalkyl; n is 1;
and R8 is C1-C6 alkyl.
5 In some embodiments, J is 0; M is alkyloxy substituted with an imaging
moiety; Q is
halo; n is 1; and Rg is C1-C6 alkyl.
In some embodiments, J is 0; and R8 is tert-butyl. In some embodiments, Q is
halo. In
some embodiments, Q is chloro. In some embodiments, M is alkyloxy substituted
with an
imaging moiety.
In some embodiments, the imaging moiety is a radioisotope for use in nuclear
medicine
imaging, a paramagnetic species for use in MR1 imaging, an eehogenic entity
for use in
ultrasound imaging, a fluorescent entity for use in fluorescence imaging, or a
light-active entity
for use in optical imaging. In some embodiments, the paramagnetic species for
use in MRI
imaging is Gd3', Fe3I, In3+, or Mn23-. In some embodiments, the echogenic
entity for use in
ultrasound imaging is a surfactant encapsulated fluorocarbon microsphere. In
some
embodiments, the radioisotope for use in nuclear medicine imaging is 11C, 13N,
ISF, 1231, 1251,
99mTC, 95TC, 111/n, 62eu, 64cu, a,
6 671..T¨ or -8Ga. In some embodiments, the imaging moiety is 18F.
It is to be understood that radiopharmaceuticals include imaging agents. Thus,
some
embodiments of the invention are described in terms of imaging agents.
81782937
6
In some embodiments, the imaging agent is selected from the group consisting
of
0 0
XaCCI
i I
N i I
N
0 Si
18F 18F
(clogP = 4.86) (clogP = 4.49) , and
0
I
N''s'N 0
(clogP = 3.04)
In one embodiment, a composition is provided comprising ascorbic acid and an
imaging
agent, wherein the imaging agent comprises pyridaben or a pyridaben analog
attached to an
imaging moiety, including a radioisotope for use in nuclear medicine imaging
such as 18F.
Synthesis methods for the various radiopharmaceuticals described herein are
known in
the art and reference can be made to published applications WO 2011006610 and
WO
2011097649.
The filtering step may be performed as follows:
A composition comprising the radiopharmaceutical is sterile filtered (e.g.,
using a
Sartorius RC or Millipore PTFE sterilizing filter) into a sterile empty vial.
The filter diameter is
typically selected based on the manufacturer's standard for the actual volume
of the composition
to be filtered. Typically, a composition volume of 5 mL, up to 10 mL, up to 20
mL, up to 30
mL, up to 40 mL, up to 50 mL or greater may be filtered. In one embodiment, a
filter with a
diameter of 4 mm may be used to filter 5 mL of a composition comprising a
radiopharmaceutical. In another embodiment, a filter with a diameter of 13 mm
may be used to
filter about 5 mL, or about 10 mL of the composition. In yet another
embodiment, a filter with a
diameter of 15 mm may be used to filter about 5 inL, or about 10 mL, or about
20 mL of a
CA 2869398 2018-06-28
CA 02869398 2014-10-01
WO 2013/173004 PCT/US2013/036027
7
composition comprising the radiopharmaceutical. In another embodiment, a
filter with a
diameter of 25 mm may be used to filter about 5 mL, or about 10 mL, or about
20 mL, or about
30 mL, or about 40 mL, or about 50 mL, or about 100 mL of the composition. The
Sartorius RC
filter is commercially available in 4, 15, and 25 mm diameters. The Millipore
PTFE filter is
.. commercially available in 13 and 25 mm diameters. The sterile empty vial
used to receive the
filtered composition may be a commercially available, pre-sterilized unit.
Those of ordinary
skill in the art would be able to select suitable sterile vials for filtration
step.
As an example, a final product vial assembly may be constructed from the
following pre-
sterilized components: one 30 mL sterile empty vial, one Millipore Millex GV4
venting filter
.. (0.22 ,fitt x 4 mm), one tuberculin syringe (1 mL) and one insulin syringe
(0.5 mL). The
imaging agent is then transferred from the formulation module of an automated
radiopharmaceutical synthesis system (such as a GE TracerLab MX or Siemens
Explora GIN/LC
module) to the final product vial assembly through a Sartorius RC sterilizing
filter (0.2 p.m x 15
mm) or a Millipore PTFE sterilizing filter (0.2 lam x 13 mm). Quality control
samples are then
.. removed, using the syringe assemblies, to complete all product release
requirements.
In accordance with the invention, a variety of experiments were carried out to
compare
the properties of particular filters; Table 1 summarizes the relevant
parameters for select filters
evaluated herein. In general, the experiments involved filtering a composition
comprising a
.. fluorinated compound, as shown below and denoted as BMS-747158-01 in the
accompanying
Figures, and its hydroxylated congener, also shown below and denoted as BMS-
747159-01 in the
accompanying Figures.
0 0
N(
G1
I I I
N
0 410 0
F 'C)H
(BMS-747158-01; log D = 2.73 0.81) and (BMS-747159-01; log D = 1.70 0.81)
In particular, compositions comprising BMS-747158-01 and BMS-747159-01 were
.. prepared in water comprising absolute ethanol (4 wt. %) and sodium
ascorbate (50 mg/mL; 5 wt.
%) then loaded into plastic syringes (NormJectTM; 12 mL) and placed onto an
automated syringe
CA 02869398 2014-10-01
WO 2013/173004 PCT/US2013/036027
8
pump. Select filters were then placed on each respective syringe and the
composition pumped
through the units in a controlled fashion. In all cases, gravimetric analysis
of the solution transfer
process was performed in order to monitor efficiency of the liquid handling
steps. Subsequent
quantitative analysis of filter retention was then performed following HPLC
determination of the
absolute concentration of each analyte in both the pre- and post-filtered
solutions; HPLC analysis
with detection at 295 nm was performed according to established methods. The
following
equation was then utilized to determine the percent recovery for each analyte:
% Recovery = final concentration volume collected
x100
inital concentration volume transferred
Note a higher value of percent recovery equates to lower retention of the
respective analyte, and
thus improved overall filter performance. The analysis described herein
captures both the mass
of the compound that is retained as well as the volume of liquid that is
retained. As no
normalization is performed, the analysis thus allows for direct comparison of
relevant filter
parameters. Further, due to the differential magnitude in measured log D
values for the
individual analytes, the value of percent recovery for BMS-747159-01 serves as
an internal
control for the study; where due to its lower inherent lipophilicity, any
mechanical problems
associated with the filtration process manifest in reduced recovery of BMS-
747159-01.
Table 1. Relevant filter parameters
= .
Model = Size (rum) . . Membrane Coating
Housing '
Millipore Millix GV 13 PVDF hydrophilic HOPE
Millipore Millix LG 13 PTFE hydrophilic HOPE
Pall Acrodisc PVDF 13 PVDF
hydrophilic PP
Pall Acrodisc GHP 13 GHP hydrophilic PP
Pall Acrodiso Nylon 13 Nylon
hydrophilic PP
Pall AcrodiscTeffryn 13 PS
hydrophilic PP
Pall Acrodisc Su Por 13 PES
hydrophilic PP
Pall Acrodisc MS 25 VVWPTFE
hydrophilic HDPE
Sartorius Nylon 25 25 Nylon hydrophilic PP
Sartorius Minisart RC 15 cellulose
hydrophilic PP
Sartorius Min isart SRP 25 PTFE hydrophobic PP
HOPE= High Density polyethylene PTFE=polytetrafluorethylene PES=
polyethersulfone
PP= Polypropylene PVDF=polyvinylidene fluoride PS=
polysulfone
CA 02869398 2014-10-01
WO 2013/173004 PCT/US2013/036027
9
The compositions comprising BMS-747158-01 and BMS-747159-01 were passed
through a variety of filters, as described herein. Individual filter
parameters varied in terms of
both membrane and housing composition, overall filter diameter, and in some
instances the
applied coating (Table 1). Further, effects of both individual analyte
concentration as well as the
overall rate of filtration were also evaluated.
FIG. 1 demonstrates the liquid transfer efficiency of the process.
Specifically, when the
same diameter filter is utilized, the relationship between the volume and
volume collected
remains relatively consistent. When larger filters are used (without a
concomitant increase in the
volume of test solution), a difference is seen. The Figure therefore
establishes that for a given
filter diameter, near complete transfer of the test composition through the
filter occurs.
FIG. 2 demonstrates the effect of filtration rate on individual analyte
recovery.
Specifically, increased overall filtration rate did not appreciably change the
recovery profiles of
either analyte.
FIG. 3 demonstrates the effect of increasing analyte concentration on
individual analyte
recovery. Specifically, the data demonstrate that the filters were not
saturated when solutions
comprising 10 ag/mL, 1 ag/mL, or 0.5 ag/mL of the individual analytes were
employed; the
recovery profiles for a given filter did not change appreciably between these
various
concentrations.
FIG. 4 demonstrates the effect of membrane composition on individual analyte
recovery.
Given filters of identical diameter, differential recovery of BMS-747158-01 is
observed for a
given membrane composition. Unexpectedly, the PVDF membrane retains the
greatest amount
of BMS-747158-01.
FIG. 5 demonstrates the effect of filter membrane and housing composition on
individual
analyte recovery. Given filters of identical diameter, it was found in
accordance with the
invention that filter housings comprising materials that lacked aromatic rings
such as high
density polyethylene (HDPE) and polypropylene (PP) retained lower amounts of
BMS-747158-
01. In contrast, filter housings comprising aromatic rings, such as
polystyrene and polyacrylates,
are less suitable.
FIG. 6 demonstrates that certain filters have high levels of non-specific
binding. An
example of such a filter is the Pall PVDF filter, which retained large amounts
of BMS-747158-
81782937
01 (but not BMS-747159-01) after the initial filtration. Interestingly, the
same filter yielded
nearly 100% recovery of BMS-747158-01 following a second filtration of the
solution matrix
itself'(10 m14, indicating that non-specific binding occurred during initial
filtration of the analyte
composition.
5 FIG. 7 demonstrates the effect of increasing filter diameter (or surface
area) on individual
analyte recovery. Specifically, the data demonstrate that larger filter
diameters retain greater
amounts of BMS-747158-01. The high recovery values for BMS-747159-01 indicate
that
mechanical retention of the solution (increased filter dead volume) did not
occur. Note the
numbers in parentheses indicate the filter diameter values.
10 FIG. 8 provides a direct comparison of selected filters. Specifically,
the data indicate that
PTFE and RC filter membranes retained lower amounts of BMS-747158-01 in
comparison to the
PVDF congener. The equivalent, yet lower percent recovery of BMS-747158-01 and
BMS-
747159-01 observed when using the 25 mm PTFE filter, however indicate that
mechanical
retention of the analyte composition may occur when utilizing filters with
larger housing
diameters.
FIG. 9 demonstrates the retention profile of the PVDF, PTFE and RC filter
membranes
for the "F-bearing radiopharmaceutical, flurpiridaz F 18 and the effect of
manual vs. automated
filtration techniques utilized with the Siemens Explora GN/LC and GE TracerEab
MX modules,
respectively. Clearly the PTFE and RC filters retain far less of the
radiopharmaceutical than
does the PVDF filter. This was particularly surprising since structurally and
chemically, the
PVDF filter is more similar to the PTFE filter than the RC filter. Further,
the data substantiate
that use of the RC filter membrane improves recovery of 18F-bearing
radiopharmaceuticals
across multiple synthesis module platforms.
These experiments demonstrate the superiority of the PTFE and RC filters for
18F-bearing
radiophannaceutieals such as flurpiridaz F 18.
In case of conflict, the present specification, including definitions,
controls.
CA 2869398 2018-06-28
